Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-08-21
1999-05-25
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424177, 424101, 530385, A61K 3816, A61K 39395, A61K 3514
Patent
active
059069740
ABSTRACT:
Low doses of stroma-free diaspirin cross-linked hemoglobin are administered to patients undergoing hemodialysis, to achieve hemostabilization and avoid hypotensive episodes in susceptible patients. Hemoglobin therapy when implemented prophylactically in hemodialysis also partially obviates the need for further interventions to control circulatory system instability.
REFERENCES:
patent: 4001401 (1977-01-01), Bonsen et al.
patent: 4757052 (1988-07-01), Markov
patent: 5296466 (1994-03-01), Kilbourn
patent: 5439882 (1995-08-01), Feola et al.
patent: 5480866 (1996-01-01), Bonaventura et al.
Medline Abstract AN 902 21208, Bergonzi et al, 1990.
Amerling et al. Complications During Hemodialysis Clinical Dialysis, Alpelton & Lang, 3rd Edition, pp. 235-267.
Bradley et al. Is Dialysis Hypotension Caused by an Abnormality of Venous Tone? Br. Med. J. (Clin. Res. Ed.), vol. 296, pp. 1634-1637, (abstract), 1988.
Kouw et al. Interestitial Correction of Blood Volume Decrease During Hemodialysis Int. J. Artif. Organs vol. 12, No. 10, pp. 626-631, (abstract), 1989.
Levin et al. Complications During Hemodialysis Clinical Dialysis, pp. 172-197.
Lubbecke et al. Plasma Catecholamines and Alpha I-Adrenoceptor Function in Hemodialysis-Associated Hypotension Ren. Fail, vol. 12, No. 4, pp. 257-261, 1990.
Maeda et al. Mechanism of Dialysis-Induced Hypotension ASAIO Trans. vol. 35., No. 3, pp. 245-247, (abstract), 1989.
Mandelbaum et al. Comment on "Baroreceptor, Not Left Ventricular, Dysfunction is the Cause of Hemodialysis Hypotension" Clin. Nephrol., vol. 32, No. 5, p. 23, (abstact), 1989.
Morrissey et al. Atrial Natriuretric Factor in Renal Failure and Posthemodialytic Postural Hypotension Am. J. Kidney Disorders, vol. 12, No. 6, pp. 510-515, (abstract), 1988.
Nakamura et al. The Role of Peripheral Capacitance and Resistance Vessels in Hypotension Following Hemodialysis Am. Heart Journal, vol. 121 No. 4, Part 1, pp. 1170-1177, (abstract), 1991.
Shimoyama et al. Changes in Catecholamine Level in Hypotensive Patients Subjected to Dialysis Nippon Jinzo Gakkai Shi, vol. 31, No. 2, pp. 165-170 (abstract), 1989.
Burhop et al. Effect of Unmodified Stroma-Reduced and Diaspirin Crosslinked Hemoglobin on the Regional Circulation and Systemic Hemodynamics FASEB J., vol. 8, No. 5, Abstract No. 3625, p. A625, 1994.
Estep et al. Diaspirin Crosslinked Hemoglobin (DCLHb): A Review of Cardiovascular and Pharmacologic Properties ISBS 1993 Program and Abstracts, (1 page).
Gulati et al. Diapsirin Cross-Linked Hemoglobin (DCLHb): Involvement of Adrenergic Mechanisms in the Pressor Effect Art. Cells, Blood Subs., and Immob. Biotech., vol. 22, No. 3, pp. 603-612, 1994.
Gulati et al. Effect of Diaspirin Crosslinked and Stroma-Reduced Hemoglobin on Mean Arterial Pressure and Endothelin-1 Concentration in Rats Life Science, vol. 56, No. 17, pp. 1433-1442, 1995.
Halstenson et al. Pharmacologic Profile of Diaspirin Cross-linked Hemoglobin (DCLHb) in Hemodialysis (HD) Patients Journal of American Society of Nephrology, vol. 5, No. 3, Abstract 84P, pp. 451, 1994.
Katsuyama et al. Nitric Oxide Mediates the Hypertensive Resonse to a Modified Hemoglobin Solution (DCLHb) in Rats Art. Cells, Blood Subs., and Immob. Biotech., vol. 22, No. 1, pp. 1-7, 1994.
Malcolm et al. Characterization of the Hemodynamic Response to Intravenous Diaspirin Crosslinked Hemoglobin Solution in Rats Art. Cells, Blood Subs., and Immob. Biotech., vol. 22, No. 1, pp. 91-107, 1994.
Przybelski et al. Clinical Studies with Diaspirin Cross-Linked Hemoglobin Solution (DCLHb): A Review and Update Art. Cells, Blood Subs., and Immob. Biotech., vol. 24, No. 4, p. 407, 1996 (abstract).
Sharma et al. Role of Nitric Oxide in Cardiovascular Effects of Diaspirin Cross-Linked (DCLHb) and Stroma Reduced Hemoglobin (SRHb) FASEB J., vol. 8, No. 5, Abstract No. 3626, p. A625, 1994.
Sharma et al. Regional Circulatory and Systemic Hemodynamic Effects of Diaspirin Cross-Linked Hemoglobin in the Rat Art. Cells, Blood Subs., and Immob. Biotech., vol. 22, No. 3, pp. 593-602, 1994.
Sherman et al. The Effect of Red Cell Transfusion on Hemodialysis-Related Hypotension Am. J. Kidney Dis., vol. 11, No. 1, pp. 33-35, 1988.
Swan et al. Pharmacologic Profile of Diaspirin Cross-Linked Hemoglobin in Hemodialysis Patients American Journal of Kidney Disease, vol. 26, No. 6, pp. 918-923, 1995.
Wyngaarden et al. Cecil Textbook of Medicine W.B. Saunders, 19th Edition, vol. 2, pp. 2162-2165, 1992.
Zietlow An Overview of DCLHb and Blood Substitutes 8th European Congress of Intensive Care Medicine, Greece, pp. 813-816, 1995.
Noris, et al., Enhanced Nitric Oxide Synthesis in Uremia Implications for Platelet Dysfunction & Dialysis Hypotension Kidney Intl., vol. 44, pp. 445-450 (1993).
Lubbecke, et al., Thrombocyte Alpha-2-Adrenoceptors and Hypotension in Hemodialyzed Patients, Nephron, vol. 68, pp. 268-269 (1994).
Fabris, et al., Conflicting Results on Peripheral Adrenoceptor Function in Hypotension of Hemodialyzed, Nephron, vol. 68, p. 270 (1994).
Yokokawa, et al., Nitric Oxide Mediates the Cardiovascular Instability of Haemodialysis Patients, Current Opinion in Nephrology and Hypertension, vol. 5, pp. 359-363 (1996).
Iada, et al., treatment of Dialysis-Inducted Hypotension with L-threo-3,4-dihydroxyphenylserine, Nephrol. Dial. Transplant, vol. 9, pp. 1130-1135 (1994).
Blue John
Garber Jan W.
Gonder Janet C.
Marchand Gary R.
Przybelski Robert J.
Baxter International Inc.
MacMillan Keith D.
LandOfFree
Hemoglobin therapy in hemodialysis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hemoglobin therapy in hemodialysis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hemoglobin therapy in hemodialysis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-401347